Coskun et al. reported LY3298176, a novel dual GIP and GLP-1R agonist for the treatment of type 2 diabetes, a study that demonstrated its potential from discovery to clinical proof-of-concept (Coskun et al., 2018). Here, GLP1R is linked to type 2 diabetes mellitus.